Detroit’s bankruptcy, while humbling and damaging to the city, has also brought “extraordinary” national interest to the Motor City, evidenced this week by the lineup of boldface technology names gathered at the Techonomy Detroit conference this week.
“It’s a sad event... Read more »
CyPhy Works has been awarded a contract with the Air Force to build a small drone for search-and-rescue operations, its second military contract.
The Danvers, MA-based company said today that it will design and test the Extreme Access Pocket Flyer, a... Read more »
At a gathering of players from the New York innovation scene, there was blunt talk and optimism about the city’s future in technology.
This week, AlwaysOn founder Tony Perkins hosted the annual OnMedia NYC summit at the NASDAQ Marketsite in Times... Read more »
The smart home is a product category marked by hype and unfulfilled promises. Now, entrepreneurs and investors think improved technology will get consumers to finally bite on home automation.
Earlier this month, Savant Systems said it raised $90 million from private equity... Read more »
A little more than a year ago, Salesforce announced it was paying $2.5 billion to acquire marketing software company ExactTarget. It was the largest in a string of buyouts meant to make Salesforce more competitive in digital marketing, giving it more... Read more »
Tokai Pharmaceuticals may be trying to break into an increasingly crowded field of prostate cancer drugs, but Wall Street investors clearly like its chances to make an impact.
Cambridge, MA-based Tokai priced its IPO at $15 per share, the top... Read more »
Third Rock Ventures started up MyoKardia in 2012 around the idea of making genetically targeted drugs for certain forms of heart disease. Two years and $38 million in venture funding into the effort, French pharmaceutical giant Sanofi is buying into the... Read more »
Seattle Angel, which over the last three years has focused on introducing more qualified people to angel investing, plans a Northwest-focused investment fund set to begin early next year.
The investments will made through the Seattle Angel Fund, a... Read more »
It wasn’t too long ago that Proteon Therapeutics looked to be a piece of Novartis’ portfolio. That deal flamed out, however, leading the Waltham, MA-based biotech to retrench, find some new investors, and—as the company as just disclosed today—chart a course... Read more »